Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Avutometinib potassium by Verastem for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Avutometinib potassium by Verastem for Metastatic Pancreatic Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Avutometinib potassium by Verastem for Metastatic Melanoma: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
Avutometinib potassium by Verastem for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Avutometinib potassium by Verastem for Fallopian Tube Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Fallopian Tube Cancer. According to GlobalData,...
Avutometinib potassium by Verastem for Cervical Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
Avutometinib potassium by Verastem for Papillary Thyroid Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Papillary Thyroid Cancer. According to GlobalData,...
Avutometinib potassium by Verastem for Anaplastic Thyroid Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Anaplastic Thyroid Cancer. According to GlobalData,...
Avutometinib potassium by Verastem for Follicular Thyroid Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Follicular Thyroid Cancer. According to GlobalData,...
Avutometinib potassium by Verastem for Metastatic Uveal Melanoma: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...
Avutometinib potassium by Verastem for Peritoneal Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Peritoneal Cancer. According to GlobalData, Phase...
Avutometinib potassium by Verastem for Ovarian Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase...